End-of-day quote
Korea S.E.
23:00:00 09/05/2024 BST
5-day change
1st Jan Change
13,940
KRW
+0.22%
+1.09%
-10.93%
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 118,321 shares, representing 0.65% for KRW 2,859.89 million.
The company expired its plan on September 8, 2022.
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023.
10/10/23
CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on April 6, 2023, has expired with 115,080 shares, representing 0.63% for KRW 1,999.72 million.
09/10/23
CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023.
13/07/23
CI
Ilyang Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
06/04/23
CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
05/04/23
CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.
08/09/22
CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 118,321 shares, representing 0.65% for KRW 2,859.89 million.
07/09/22
CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine
12/04/22
MT
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
10/03/22
CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
09/03/22
CI
Ilyang Pharmaceutical Co.,Ltd(KOSE:A007570) dropped from KOSPI 200 Index
09/12/21
CI
Boryung Pharmaceutical : S.Korea sticks to flu vaccine plan despite safety fears after 25 die
22/10/20
RE
Boryung Pharmaceutical : Number of South Koreans dying after flu shot rises, prompts vaccine worries
22/10/20
RE
Il-Yang Pharmaceutical Signs Licence with Laboratorios Biopas to Export Leukemia Drug Supect to Colombia
05/09/16
CI
Ilyang Pharmaceutical Co., Ltd announced that it has received KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Investment & Securities Co.,Ltd., and SBI Savings Bank Inc., Investment Arm.
13/06/14
CI
Ilyang Pharmaceutical Co., Ltd announced that it expects to receive KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Private Equity, and SBI Savings Bank Inc., Investment Arm.
12/06/14
CI
Ilyang Pharmaceutical Co., Ltd's Equity Buyback Plan Extended till September 25, 2022.
18/09/12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Ilyang Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The Company also produces products including nourishing tonics and health supplements, among others.
More about the company
1st Jan change
Capi.
-10.93% 183M +20.60% 43.27B +25.28% 22.92B +19.62% 15.43B +13.75% 12.95B +44.18% 11.83B -7.79% 6.91B -0.05% 6.79B -8.87% 5.73B +13.13% 5.55B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1